Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole in Low-grade Serous Ovarian Cancer (LEPRE)
NCT05601700Phase 3Recruiting
- Sponsor
- Ospedali Galliera
- Start
- Sep 2022
- Primary completion
- Sep 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of letrozole in Low grade serous ovarian cancer (LGSOC), sponsored by Ospedali Galliera. Started Sep 2022; status: recruiting.
02
Drugs
letrozole
03
Conditions
Low grade serous ovarian cancer (LGSOC)
Beyond the preview
Go deeper on NCT05601700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05601700.